Today: 22 March 2026
Subscribe
Browse Category

Stock Market 30 December 2025

S&P Global (SPGI) stock slips near $529 as Fed minutes, year-end flows keep Wall Street muted

S&P Global (SPGI) stock slips near $529 as Fed minutes, year-end flows keep Wall Street muted

S&P Global shares slipped 0.16% to $529.25 Tuesday after its Mobility unit forecast a 2.5% drop in 2026 U.S. auto sales, citing affordability concerns. Moody’s and MSCI also traded lower. Major U.S. index ETFs hovered near flat in thin year-end trading. S&P Global Mobility projects 2026 U.S. light-vehicle sales at 15.89 million units, down from a projected 16.3 million for 2025.
30 December 2025
··
SRRK stock drops 3% today: What’s driving Scholar Rock shares as FDA reinspection nears

SRRK stock drops 3% today: What’s driving Scholar Rock shares as FDA reinspection nears

Scholar Rock shares fell 3.2% to $43.76 Tuesday afternoon, underperforming biotech peers as investors watched for updates on FDA reinspection timing for its lead drug, apitegromab. The company aims to resubmit its biologics license application in 2026 after the Indiana fill-finish site, now owned by Novo Nordisk, completes remediation and is reinspected by year-end 2025.
30 December 2025
·
Progressive stock ticks higher today after SEC filing flags 87,755-share gift; what investors watch next

Progressive stock ticks higher today after SEC filing flags 87,755-share gift; what investors watch next

Progressive shares rose 0.7% to $230 Tuesday after a regulatory filing showed director Charles A. Davis donated 87,755 shares to a charitable foundation. The stock traded between $227.53 and $230.03 on volume of about 1 million shares. U.S. insurance stocks edged higher in thin year-end trading. Davis retained 250,222 shares after the transaction.
30 December 2025
···
GRAIL stock drops in New York session as Galleri FDA filing timeline returns to focus

GRAIL stock drops in New York session as Galleri FDA filing timeline returns to focus

GRAIL shares dropped 3.3% to $84.95 Tuesday afternoon, extending a two-day slide. An Oregon Health & Science University release highlighted PATHFINDER 2 data and confirmed a first-quarter 2026 FDA submission for Galleri. Investors await management’s Jan. 12 update at the J.P. Morgan Healthcare Conference. The stock is down 7.2% since Friday’s close.
30 December 2025
··
Bloom Energy stock slips today as Clear Street lifts target but keeps Hold in thin year-end trade

Bloom Energy stock slips today as Clear Street lifts target but keeps Hold in thin year-end trade

Bloom Energy shares fell 1.7% to $86.93 in afternoon trading Tuesday, moving between $90.11 and $86.00 on light holiday volume. Clear Street raised its price target to $58 but kept a Hold rating, citing data-center capacity expectations. Bloom disclosed a new $600 million revolving credit facility led by Wells Fargo in a Dec. 23 SEC filing. Peers Plug Power and FuelCell Energy also declined.
30 December 2025
··
American Airlines stock edges up today as Chicago O’Hare expansion and storm fallout stay in focus

American Airlines stock edges up today as Chicago O’Hare expansion and storm fallout stay in focus

American Airlines shares rose 0.6% to $15.24 Tuesday after announcing 100 additional peak daily departures from Chicago O’Hare for spring. The carrier also plans to extend summer service to Paris and Dublin. Investors are watching for winter-storm impacts and fuel costs ahead of expected late-January results. Airline stocks had dropped Monday as Winter Storm Ezra disrupted travel.
30 December 2025
···
TIC Solutions (TIC) stock slides 3.5% today as Fed minutes and thin year-end trade set the tone

TIC Solutions (TIC) stock slides 3.5% today as Fed minutes and thin year-end trade set the tone

TIC Solutions shares dropped 3.5% to $10.02 in thin year-end trading Tuesday, underperforming a steady U.S. market. The decline followed Federal Reserve minutes showing policy divisions and came as investors awaited January jobs and inflation data. Trading volume in TIC lagged its recent average, and peers Mistras Group and Jacobs Solutions slipped less than 1%.
30 December 2025
··
Applied Materials stock slips as China’s 50% domestic chip-tool rule puts AMAT in the spotlight

Applied Materials stock slips as China’s 50% domestic chip-tool rule puts AMAT in the spotlight

Applied Materials shares fell 1.1% to $260.27 Tuesday after Reuters reported China now requires chipmakers expanding capacity to source at least 50% of equipment domestically. The iShares Semiconductor ETF was little changed. Wells Fargo raised its price target on Applied Materials to $290 and maintained an Overweight rating. Lam Research and KLA shares also slipped about 1%.
30 December 2025
·····
Catalyst Pharmaceuticals stock drops 3% today as CPRX lags biotech in thin year-end trade

Catalyst Pharmaceuticals stock drops 3% today as CPRX lags biotech in thin year-end trade

Catalyst Pharmaceuticals shares fell 3% to $23.33 in thin afternoon trading Tuesday, extending a two-day slide and leaving the stock about 12% below its June high. Biotech ETFs underperformed the broader market, with the iShares Nasdaq Biotechnology ETF down 1.2%. Investors are awaiting the Federal Reserve’s meeting minutes and Catalyst’s next update in January.
30 December 2025
··
Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching

Kymera Therapeutics (KYMR) stock falls today as biotech slips — what traders are watching

Kymera Therapeutics shares fell 3% to $77.94 Tuesday afternoon, underperforming a 1.4% drop in the SPDR S&P Biotech ETF. The decline follows December’s $692 million equity raise and positive Phase 1b data for its STAT6 degrader KT-621. The stock traded about 9% below its recent $86 offering price. Investors are watching for updates on trial progress and cash burn ahead of 2026 milestones.
30 December 2025
··
Almonty Industries stock today: ALM slips as CBS report spotlights U.S. tungsten supply deal

Almonty Industries stock today: ALM slips as CBS report spotlights U.S. tungsten supply deal

Almonty Industries shares fell 3.9% to $8.90 Tuesday after early gains, trading between $8.90 and $9.39. The drop followed news that CEO Lewis Black met U.S. officials and signed a deal tied to future tungsten supply from the Sangdong mine in South Korea, which is set to start production in early 2026. Almonty recently raised $129.4 million in a U.S. share sale and delivered its first ore to Sangdong’s staging area.
30 December 2025
···
1 … 716 717 718 719 720 … 1,358

Stock Market Today

  • AstraZeneca Share Price Falls 9% in a Month, Analysts See Upside Potential
    March 22, 2026, 2:33 PM EDT. AstraZeneca (LSE:AZN) shares slipped nearly 9% over the past month, tempering gains from a 21.8% total return over the last year. Despite this short-term price weakness, analyst sentiment remains constructive, updating the fair value estimate to £162.67 from £152.79, suggesting the stock is undervalued at its current £138.96 price. This revision reflects expectations of stronger earnings, improved margins, and a richer product mix. However, risks loom, including potential price pressure on key drugs and high research and development costs that may delay approvals. Investors are advised to consider both the opportunities and warnings before adjusting positions, also exploring other healthcare stocks for diversification.
Go toTop